ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 279 filers reported holding ACADIA PHARMACEUTICALS INC in Q4 2019. The put-call ratio across all filers is 0.89 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $321,000 | +121.4% | 22,813 | +280.0% | 0.01% | +140.0% |
| Q1 2022 | $145,000 | +705.6% | 6,003 | +664.7% | 0.01% | +400.0% |
| Q4 2021 | $18,000 | -86.0% | 785 | -89.9% | 0.00% | -75.0% |
| Q3 2021 | $129,000 | -44.2% | 7,747 | -18.3% | 0.00% | -42.9% |
| Q2 2021 | $231,000 | +11.6% | 9,488 | +18.1% | 0.01% | 0.0% |
| Q1 2021 | $207,000 | -67.2% | 8,033 | -38.3% | 0.01% | -90.0% |
| Q2 2020 | $631,000 | +4753.8% | 13,026 | +4315.6% | 0.07% | +2233.3% |
| Q4 2019 | $13,000 | -76.4% | 295 | -91.8% | 0.00% | -84.2% |
| Q2 2018 | $55,000 | -45.0% | 3,591 | -19.1% | 0.02% | -63.5% |
| Q1 2018 | $100,000 | +614.3% | 4,439 | +822.9% | 0.05% | +372.7% |
| Q4 2017 | $14,000 | +600.0% | 481 | +862.0% | 0.01% | +1000.0% |
| Q3 2017 | $2,000 | -90.5% | 50 | -91.9% | 0.00% | -96.3% |
| Q1 2017 | $21,000 | -40.0% | 619 | -49.4% | 0.03% | -22.9% |
| Q4 2016 | $35,000 | – | 1,223 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 556,553 | $11,598,565 | 5.78% |
| Baker Brothers Advisors | 42,864,612 | $893,298,514 | 5.15% |
| RTW INVESTMENTS, LP | 11,576,537 | $241,255,031 | 5.09% |
| Palo Alto Investors LP | 2,405,793 | $50,136,726 | 4.74% |
| Birchview Capital, LP | 240,400 | $5,009,936 | 4.26% |
| EcoR1 Capital, LLC | 5,991,479 | $124,862,422 | 4.21% |
| EMERALD ADVISERS, LLC | 1,681,052 | $35,033,124 | 1.70% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 1,303,988 | $27,175,110 | 1.64% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 179,702 | $3,739,599 | 1.26% |
| SECTOR GAMMA AS | 179,785 | $3,746,719 | 0.96% |